DOH, DOST kinalampag sa Ivermectin CLINICAL TRIALS BILISAN – DEFENSOR

0

HINILING ni Anakalusugan party-list Rep. Mike Defensor sa Department of Health (DOH) at Department of Science and Technology (DOST) na bilisan ang clinical trial sa Ivermectin at huwag nang paabutin ng ilang buwan upang mailigtas ang buhay ng mga tao sa COVID-19.

“Lives are at stake here. We could save many lives with the use of this popular P35-per-tablet experimental drug. The results of the trials ordered by President Duterte should be available soon,” ani Defensor.

Ayon sa mambabatas, mismong si Pangulong Rodrigo Duterte na ang nag-utos na isailalim sa clinical trial ang Ivermectin dahil maraming mahihirap na tinamaan ng COVID-19 ang gustong gumamit ng nasabing gamot subalit ang ibinibigay sa mga ito ay Remdesivir at Tocilizumab na sobra ang mahal.

Bukod dito, experimental therapeutics lamang umano ang Remdevisir at Tocilizumab subalit ito ang mas pinaboran ng DOH at FDA habang sinisiraan naman ang Ivermectin.

“The poor can afford a P35 drug. In the case of its two other rivals, they cost thousands, if one can find them in the market,” ayon pa sa mambabatas.

Karaniwang inaabot ng 6 na buwan para matapos ang isang pag-aaral sa gamot subalit ayon kay Defensor, hindi na kailangang abutin ng ganito katagal dahil marami nang pruweba sa ibang bansa na epektibo ang gamot na ito laban sa COVID-19.

Gayunman, inamin ni Defensor na hindi pa pinapayagan ng WHO ang paggamit sa Ivermectin.

“But the WHO is also against the use of Remdesivir, and yet the DOH and the Food and Drug Administration (FDA) are promoting it. In fact, the DOH is spending millions in taxpayers’ money to procure Remdesivir and distribute it to government hospitals,” paliwanag nito.

Dahil dito, hindi maintindihan ng mambabatas kung bakit pinagagamit ng DOH ang napakamahal na gamot na experimental drug pa lamang samantalang ayaw nilang ipagamit ang Ivermectin na bukod sa mura ay may sapat na supply sa merkado.

“Can the DOH and FDA allow the use of Ivermectin? Yes, they can, if they want to. In fact, the FDA is allowing it on a patient-to-patient basis. Why not permit its use on a wider scale so it would be available to more patients, especially the poor,” ani Defensor.

Sa pagdinig ng House committee on good government and public accountability, sinabi ni Defensor na hindi kaya ng mahihirap ang presyo ng Remdesivir dahil sa isang ospital aniya sa Marikina ay nagkakahalaga ito ng P1,762.50 habang sa isang pagamutan sa Quezon City ay ibinibenta ito ng P48,241.

Sa Sta. Rosa, Laguna aniya, isang pasyente ang siningil ng P9,940 habang sa isang health facility naman sa Angono, Rizal ay ibinebenta ito sa halagang P27,300; P19,000 sa Pagadian City, P11,000 sa Gen. Trias, Cavite, gayung ang original price nito ay P1,950 hanggang P6,200 lamang.

“Some people are obviously raking in a lot of money from the sale of this drug, and the DOH and FDA are abetting it. Did the drug save lives?

I hoped so, but we don’t know,” ani Defensor. (BERNARD TAGUINOD)

 
"COMMENT DISCLAIMER: Reader comments posted on this Web site are not in any way endorsed by SAKSI NGAYON. Comments are views by saksingayon.com readers who exercise their right to free expression and they do not necessarily represent or reflect the position or viewpoint of saksingayon.com. While reserving this publication’s right to delete comments that are deemed offensive, indecent or inconsistent with SAKSI NGAYON editorial standards, SAKSI NGAYON may not be held liable for any false information posted by readers in this comments section."

Related posts

Leave a Comment